A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for immunotherapy of malignant melanoma

被引：10

作者：

Jabulowsky, Robert A. ^{[1
]}

Loquai, Carmen ^{[2
]}

Mitzel-Rink, Heidrun ^{[2
]}

Utikal, Jochen ^{[3
,4
]}

Gebhardt, Christoffer ^{[3
,4
]}

Hassel, Jessica C. ^{[5
]}

Kaufmann, Roland ^{[6
]}

Pinter, Andreas ^{[6
]}

Derhovanessian, Evelyna ^{[1
]}

Anft, Christine ^{[1
]}

Attig, Sebastian ^{[7
]}

Deubel, Alexandra ^{[1
]}

Diken, Mustafa ^{[7
]}

Gold, Maike ^{[1
]}

Guertler, Claudia ^{[1
]}

Haas, Heinrich ^{[1
]}

Heesen, Ludwig ^{[1
]}

Kemmer-Brueck, Alexandra ^{[1
]}

Kranz, Lena M. ^{[1
]}

Kuehlcke, Klaus ^{[1
]}

Kuhn, Andreas ^{[1
]}

Langguth, Peter ^{[1
]}

Luxemburger, Ulrich ^{[1
]}

Maurus, Daniel ^{[1
]}

Meng, Martin ^{[1
]}

Mueller, Felicitas ^{[1
]}

Rae, Richard ^{[6
,7
]}

Sari, Fatih ^{[1
]}

Schreeb, Katharina ^{[1
]}

Schwarck-Kokarakis, Doreen ^{[1
]}

Stein, Malte ^{[1
]}

Jaeger, Dirk ^{[8
]}

Grabbe, Stephan ^{[2
]}

Kreiter, Sebastian ^{[6
,7
]}

Huber, Christoph ^{[1
]}

Tuereci, Oezlem ^{[9
]}

Sahin, Ugur ^{[1
]}

机构：

[1] BioNTech Corp, Mainz, Germany

[2] Univ Med Ctr Mainz, Dept Dermatol, Mainz, Germany

[3] German Canc Res Ctr, Skin Canc Unit, Heidelberg, Germany

[4] Heidelberg Univ, Univ Med Ctr Mannheim, Dept Dermatol Venereol & Allergol, Mannheim, Germany

[5] Heidelberg Univ Hosp, NCT Heidelberg, Dept Dermatol, Heidelberg, Germany

[6] Goethe Univ Frankfurt, Dept Dermatol Venereol & Allergol, Frankfurt, Germany

[7] Univ Med Ctr Mainz gGmbH, TRON Translat Oncol, Mainz, Germany

[8] Univ Hosp Heidelberg, Natl Ctr Tumor Dis, Med Oncol, Heidelberg, Germany

[9] Cluster Individualized Immune Intervent, Mainz, Germany

来源：

CANCER RESEARCH | 2018年 / 78卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2018-CT156

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT156

引用

页数：3

共 37 条

[31] Safety and Immunogenicity of Betuvax-CoV-2, an RBD-Fc-Based SARS-CoV-2 Recombinant Vaccine: Preliminary Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase I/II Clinical Trial
Kudriavtsev, Aleksandr V.
Vakhrusheva, Anna V.
Kryuchkov, Nickolay A.
Frolova, Maria E.
Blagodatskikh, Konstantin A.
Ivanishin, Taras V.
Djonovic, Milana
Romanovskaya-Romanko, Ekaterina A.
Kovalenko, Anton N.
Lioznov, Dmitry A.
Zubkova, Tatiana G.
Teplykh, Svetlana V.
Oseshnyuk, Rodion A.
Stukova, Marina A.
Isaev, Artur A.
Krasilnikov, Igor V.
VACCINES, 2023, 11 (02)
[32] Phase I-II first-in-human clinical trial of intraputamenal CDNF in Parkinson's disease: Topline results of the six-month double-blind placebo-controlled main study and the six-month active treatment extension study
Booms, S.
Huttunen, H.
Koskinen, J.
Sjogren, M.
Saarma, M.
Woolley, M.
Murphy, B.
Fielder, P.
Baker, J.
Skinner, P.
Rinne, J.
Varrone, A.
Andreasson, M.
Paul-Visse, G.
Kivisaari, R.
Bjartmarz, H.
Lind, G.
Almqvist, P.
Scheperjans, F.
Widner, H.
Svenningsson, P.
MOVEMENT DISORDERS, 2020, 35 : S390 - S390
[33] First-in-human phase I clinical trial of NY-ESO-1 protein cancer vaccine with a novel adjuvant MIS416, NOD2 and TLR9 stimulant, for patients with NY-ESO-1 expressing solid tumors.
Ishihara, Mikiya
Tono, Yasutaka
Miyahara, Yoshihiro
Harada, Naozumi
Kageyama, Shinichi
Sasaki, Takeshi
Hori, Yasuhide
Soga, Norihito
Uchida, Katsunori
Shiraishi, Taizo
Sato, Eiichi
Kanda, Hideki
Mizuno, Toshiro
Webster, Gill
Ikeda, Hiroaki
Katayama, Naoyuki
Sugimura, Yoshiki
Shiku, Hiroshi
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[34] First-in-human first-in-class phase I trial of murlentamab, an anti-Mullerian-hormone receptor II (AMHRII) monoclonal antibody acting through tumor-associated macrophage (TAM) engagement, as single agent and in combination with carboplatin (C) and paclitaxel (P) in AMHRII-expressing advanced/metastatic gynecological cancer patients (pts)
Leary, Alexandra
Awada, Ahmad
Delord, Jean-Pierre
Floquet, Anne
Ray-Coquard, Isabelle Laure
Abdeddaim, Cyril
Fabbro, Michel
Kalbacher, Elsa
Vergote, Ignace
Banerjee, Susana N.
Frenois, Francois-Xavier
Noel, Gregory
Lantz, Olivier
Cassard, Lydie
Coste, Agnes
Villard, Marine
Lemee, Fanny
Tabah-Fisch, Isabelle Marie
Le Tourneau, Christophe
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[35] Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial
Mahomed, Sharana
Garrett, Nigel
Karim, Quarraisha A.
Zuma, Nonhlanhla Y.
Capparelli, Edmund
Baxter, Cheryl
Gengiah, Tanuja
Archary, Derseree
Samsunder, Natasha
Rose, Nicole D.
Moore, Penny
Williamson, Carolyn
Barouch, Dan H.
Fast, Patricia E.
Pozzetto, Bruno
Hankins, Catherine
Carlton, Kevin
Ledgerwood, Julie
Morris, Lynn
Mascola, John
Abdool Karim, Salim
BMJ OPEN, 2020, 10 (11):
[36] A novel and uniquely designed bispecific antibody (LBL-024) against PD-L1 and 4-1BB in patients with advanced malignant tumors and neuroendocrine carcinoma: A report of safety and robust efficacy of LBL-024 monotherapy in phase I/II, first-in-human, open-label, multicenter, dose escalation/expansion study
Lu, Ming
Zhang, Panpan
Luo, Suxia
Chen, Jie
Yang, Jianwei
Song, Zhengbo
Li, Yongsheng
Tang, Ying
Zhao, Peng
Liu, Baorui
Li, Junhe
Hu, Sheng
Zhang, Zhiye
Wu, Lin
Song, Lijie
Feng, Xielin
Shan, Yunfeng
Liu, Tao
Cai, Shengli
Shen, Lin
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[37] A novel fully human monoclonal antibody against epidermal growth factor receptor (EGFR). First clinical and FDG-PET imaging results from a phase I/II trial conducted by the Danish Head and Neck Cancer Study Group (DAHANCA) in patients with squamous cell carcinoma of the head and neck (SCCHN).
Bastholt, L
Specht, L
Jensen, K
Brun, E
Loft, A
Petersen, J
Kastberg, H
Eriksen, JG
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 507S - 507S

← 1 2 3 4 →